Although CCL2, CCL3 and their receptors have been previously detected in inflammatory and glial cells in MS lesions, their role in the chemoattraction of T cell subsets to sites of antigenic challenge in the brain has not been previously addressed. This evidence concerns the gene CCL2 and myeloid sarcoma.